Objetivo: Evaluar el impacto sobre la incidencia y recurrencia de eventos cardiovasculares y cerebrovasculares (prevención primaria y secundaria), los niveles de las fracciones lipídicas y la incidencia de efectos secundarios en personas con hipercolesterolemia intolerantes al tratamiento con las estatinas. Métodos: Se elaboró una guía de práctica clínica siguiendo los lineamientos de la guía metodológica del Ministerio de Salud y Protección Social para recolectar de forma sistemática la evidencia científica y formular las recomendaciones utilizando la metodología GRADE. Población: Población adulta, con diagnóstico de dislipidemia, o en riesgo de desarrollarla, intolerantes al manejo con las estatinas. Recomendaciones: Se formulan recome...
Many patients undergoing treatment with lipid-lowering drugs do not reach their therapeutic goal for...
<p>Statins are used to reduce morbidity and mortality in patients with a high risk of cardiovascular...
The key role of dyslipidaemia in determining cardiovascular disease (CVD) has been proved beyond rea...
ResumenObjetivoEvaluar el impacto sobre la incidencia y recurrencia de eventos cardiovasculares y ce...
Objetivo Evaluar el impacto del tratamiento con estatinas sobre la incidencia y la recurrencia de l...
Importance of the field: Lipid-modifying drugs are therapeutic options that have been shown to reduc...
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) and its clinical manifestations, rem...
The importance of treating dyslipidemias based on cardiovascular risk factors is highlighted by the ...
Pharmacologic agents including hydroxymethylglutarylcoenzyme A (HMG-CoA) reductase inhibitors (stati...
Objetivo: Evaluar el impacto del ejerciciocomo una intervención no farmacológica parala prevención p...
Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of cor...
Objective: We present an update of the Spanish Society of Neurology's recommendations for prevention...
introduction: Drug use studies are important to evaluate the effectiveness and safety of drugs in da...
Introduction: Dyslipidemia is a group of diseases whose common characteristic is the abnormal concen...
La aterosclerosis y sus complicaciones son la primera causa de morbilidad y mortalidad en el mundo...
Many patients undergoing treatment with lipid-lowering drugs do not reach their therapeutic goal for...
<p>Statins are used to reduce morbidity and mortality in patients with a high risk of cardiovascular...
The key role of dyslipidaemia in determining cardiovascular disease (CVD) has been proved beyond rea...
ResumenObjetivoEvaluar el impacto sobre la incidencia y recurrencia de eventos cardiovasculares y ce...
Objetivo Evaluar el impacto del tratamiento con estatinas sobre la incidencia y la recurrencia de l...
Importance of the field: Lipid-modifying drugs are therapeutic options that have been shown to reduc...
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) and its clinical manifestations, rem...
The importance of treating dyslipidemias based on cardiovascular risk factors is highlighted by the ...
Pharmacologic agents including hydroxymethylglutarylcoenzyme A (HMG-CoA) reductase inhibitors (stati...
Objetivo: Evaluar el impacto del ejerciciocomo una intervención no farmacológica parala prevención p...
Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of cor...
Objective: We present an update of the Spanish Society of Neurology's recommendations for prevention...
introduction: Drug use studies are important to evaluate the effectiveness and safety of drugs in da...
Introduction: Dyslipidemia is a group of diseases whose common characteristic is the abnormal concen...
La aterosclerosis y sus complicaciones son la primera causa de morbilidad y mortalidad en el mundo...
Many patients undergoing treatment with lipid-lowering drugs do not reach their therapeutic goal for...
<p>Statins are used to reduce morbidity and mortality in patients with a high risk of cardiovascular...
The key role of dyslipidaemia in determining cardiovascular disease (CVD) has been proved beyond rea...